Five Days Before Year End
You are the divisional controller of a medical device distributor with a 31 December fiscal year end. Five working days before close, the sales vice president proposes shipping $2.1 million of orders to three distributors on terms that differ from the standard contract: 120-day payment, and a right of return that is not in the standard terms and has never been offered to these customers. The stated purpose is to reach the division's revenue target. Two of the three distributors have ordered these SKUs only once before; the third is currently 90 days past due on an unrelated invoice. The CEO has been briefed and says the distributors 'always send some back anyway, it's just paperwork.' Divisional management bonuses are calculated on revenue, and the sales VP's bonus for the year depends on this shipment. The external auditor will test cut-off and return provisions in January. Your CFO asks whether you are comfortable signing the revenue schedule.
1. Analyse the accounting and ethical issues in this proposal. Distinguish what is clearly wrong from what requires judgement.
Read the worked answer
Requires judgement, but points strongly one way:
- Transfer of control. Revenue is recognised when control passes. Goods sitting with a distributor who holds a return right, on extended terms, with no history of this arrangement, are weak evidence of control transfer. The question is not 'did it leave the warehouse' but 'is the customer genuinely obliged to keep it'.
- Variable consideration. A right of return makes part of the price variable and must be constrained to the amount highly probable of not reversing. With no history on these SKUs and these customers, the constraint bites hard: the historical 4% return rate on other products is not a reliable basis for a new arrangement.
- Collectibility. The 120-day terms on a customer already 90 days past due is a red flag; a portion of the $2.1 million may not meet the probability-weighted collectibility test.
- Significant financing component may be present given 120-day terms.
Clearly wrong: designing the terms of a transaction to achieve a reporting outcome rather than a commercial one, and doing so with five days left in the year, is earnings management. The CEO's 'it's just paperwork' framing is precisely the tone-at-the-top condition that regulators and auditors treat as an aggravating factor.
Ethical dimension: bonuses tied to revenue, a personal financial stake for the VP, and pressure on the controller to sign. The IMA-style test applies: is it legal, does it fairly reflect economics, and would you be comfortable if the terms and the rationale were disclosed verbatim in the annual report? The answer to the third is no.
2. Set out your escalation path and the exact way you would frame the objection so that it is heard as a business risk, not obstruction.
Read the worked answer
Sequence, not simultaneity. Escalate internally first, in writing, quickly.
- Reply to the CFO within 24 hours. Not 'I'm not comfortable', but a specific position: 'I cannot sign the schedule as proposed. I can sign it if (a) the return right is removed, (b) terms are standard 60-day, and (c) the past-due distributor prepays or provides security. Alternatively, we ship and do not recognise revenue until the return window lapses.' Give a compliant route, not just a refusal. Controllers who only say no get bypassed.
- Ask for a joint call with the CEO, CFO and sales VP. Frame it as: this is a $2.1 million revenue question with a possible restatement attached, and both of those are worse than a missed target. Bring the specific auditor test: cut-off testing on late-December shipments with non-standard terms is a standard procedure and this will be found.
- If the CEO instructs the shipment to be recognised anyway: state your objection in writing, note the accounting basis, decline to certify the schedule, and escalate to the audit committee chair. That is a legitimate last internal step, not disloyalty.
- Use the whistleblower or ethics channel if there is any indication of documents being altered or the auditor being misled. Misleading an auditor moves this from accounting judgement to a legal matter - involve legal counsel.
Framing rules: lead with the restatement risk and the auditor's likely finding, quantify where you can, avoid accusing anyone of intent, and always present an alternative that lets sales pursue the revenue legitimately.
3. The CEO wants the $2.1 million of revenue and the distributor relationships. What legitimate alternatives would you put on the table?
Read the worked answer
Start by separating the two goals. The commercial goal - moving product and preserving distributor relationships - is legitimate. The reporting goal, hitting a target that the underlying demand does not support, is not, but there are honest ways to close part of the gap.
Options:
- Ship on standard terms to the two clean distributors. Real orders, ordinary contract, revenue recognised normally. Accept the smaller number.
- Negotiate a genuine, non-returnable commitment with a price incentive - for example a modest discount or extended payment terms without a return right, where the distributor is contractually obliged. That is a real sale at a real (lower) margin, and it is disclosable.
- Bill-and-hold in the narrow cases where the criteria are genuinely met (customer requested it, goods identified and segregated, ready to ship, no ability to use them elsewhere) - but not as a device to pull forward sales that the customer does not want.
- Fix the forecast process. If the year-end gap is structural, the right output is a revised full-year expectation communicated early, not a scramble in the last week. Propose to the CFO that the board be given a realistic number now rather than an optimistic one that unwinds in Q1.
- Address the incentive design. Revenue-only bonuses with no return, margin or cash-collection qualifier will keep producing this conversation every December. Recommend that the compensation committee add a returns and DSO modifier. That is the durable fix; the transaction is only the symptom of it.